Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Cash (2020 - 2025)

Cytek Biosciences' Change in Cash history spans 6 years, with the latest figure at -$2.4 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 96.18% year-over-year to -$2.4 million; the TTM value through Dec 2025 reached -$7.9 million, up 88.54%, while the annual FY2025 figure was -$7.9 million, 88.54% up from the prior year.
  • Change in Cash reached -$2.4 million in Q4 2025 per CTKB's latest filing, down from $17.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $409.2 million in Q4 2021 to a low of -$204.4 million in Q3 2021.
  • Average Change in Cash over 5 years is -$3.8 million, with a median of -$2.9 million recorded in 2025.
  • Peak YoY movement for Change in Cash: crashed 99313.11% in 2021, then soared 1132.59% in 2024.
  • A 5-year view of Change in Cash shows it stood at $409.2 million in 2021, then tumbled by 110.27% to -$42.0 million in 2022, then skyrocketed by 109.52% to $4.0 million in 2023, then crashed by 1688.55% to -$63.6 million in 2024, then surged by 96.18% to -$2.4 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Change in Cash are -$2.4 million (Q4 2025), $17.8 million (Q3 2025), and -$19.8 million (Q2 2025).